- Email: [email protected]
Corrigendum to “Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey” [Drug Alcohol Depend., 105(1–2) 2009 83–88]
Drug and Alcohol Dependence 113 (2011) 252
Contents lists available at ScienceDirect
Drug and Alcohol Dependence journal homepage: www.elsevier.com/locate/drugalcdep
Corrigendum
Corrigendum to “Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey” [Drug Alcohol Depend., 105(1–2) 2009 83–88] Amy Nunn a,b,∗ , Nickolas Zaller a,b,c , Samuel Dickman a , Catherine Trimbur d , Anka Nijhawan a,b , Josiah D. Rich a,b,c a
Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA c Center for Prisoner Health and Human Rights, Providence, RI 02906, USA d University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA b
In this paper, we surveyed the medical directors of state, federal, and District of Columbia prison systems about their opinions and prescribing practices for methadone and buprenorphine. Our survey also included questions about prison policies related to referring prisoners to community-based opiate replacement therapy (ORT) programs upon release. A color-coded map was used to illustrate states’ prescribing and referral policies (Fig. 1). The original map indicated that the District of Columbia offered only ORT referrals. We found in our survey, however, that the District of Columbia offered both ORT and ORT referrals and was thus mislabeled on the map as medium blue instead of dark blue. Below is the correct Fig. 1.
Fig. 1. Current status of state prison systems offering opiate replacement therapy (ORT) and referrals to community-based ORT providers.
DOI of original article:10.1016/j.drugalcdep.2009.06.015. ∗ Corresponding author at: Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA. E-mail address: amy [email protected] (A. Nunn). 0376-8716/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.drugalcdep.2010.07.002
Contents lists available at ScienceDirect
Drug and Alcohol Dependence journal homepage: www.elsevier.com/locate/drugalcdep
Corrigendum
Corrigendum to “Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey” [Drug Alcohol Depend., 105(1–2) 2009 83–88] Amy Nunn a,b,∗ , Nickolas Zaller a,b,c , Samuel Dickman a , Catherine Trimbur d , Anka Nijhawan a,b , Josiah D. Rich a,b,c a
Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA c Center for Prisoner Health and Human Rights, Providence, RI 02906, USA d University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA b
In this paper, we surveyed the medical directors of state, federal, and District of Columbia prison systems about their opinions and prescribing practices for methadone and buprenorphine. Our survey also included questions about prison policies related to referring prisoners to community-based opiate replacement therapy (ORT) programs upon release. A color-coded map was used to illustrate states’ prescribing and referral policies (Fig. 1). The original map indicated that the District of Columbia offered only ORT referrals. We found in our survey, however, that the District of Columbia offered both ORT and ORT referrals and was thus mislabeled on the map as medium blue instead of dark blue. Below is the correct Fig. 1.
Fig. 1. Current status of state prison systems offering opiate replacement therapy (ORT) and referrals to community-based ORT providers.
DOI of original article:10.1016/j.drugalcdep.2009.06.015. ∗ Corresponding author at: Alpert Medical School of Brown University, Division of Infectious Diseases, 164 Summit Avenue, Providence, RI 02906, USA. E-mail address: amy [email protected] (A. Nunn). 0376-8716/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.drugalcdep.2010.07.002